Literature DB >> 23456862

The regenerative activity of interleukin-6.

Eithan Galun1, Stefan Rose-John.   

Abstract

Interleukin-6 (IL-6) is a cytokine which is involved in many inflammatory processes and in the development of cancer. In addition, IL-6 has been shown to be important for the induction of hepatic acute-phase proteins, for the regeneration of the liver and for the stimulation of B-cells. IL-6 binds to a transmembrane IL-6 receptor (IL-6R), which is present on hepatocytes and some leukocytes. The complex of IL-6 and IL-6R associates with a second protein, gp130, which is expressed on all cells of the body. Since neither IL-6 nor IL-6R has a measurable affinity for gp130, cells, which do not express IL-6R, are not responsive to the cytokine IL-6. It could be shown, however, that a naturally occurring soluble IL-6R (sIL-6R) in complex with IL-6 can bind to gp130 on cells with no IL-6R expression. Therefore, cells shedding the sIL-6R render cells, which only express gp130, responsive to the cytokine. This process has been called trans-signaling. In the present chapter, we summarize the known activities of IL-6 with a special emphasis on regenerative activities, which often depend on the sIL-6R. A designer cytokine called Hyper-IL-6, which is a fusion protein of IL-6 and the sIL-6R, can mimic IL-6 trans-signaling responses in vitro and in vivo with considerably higher efficacy than the combination of the natural proteins IL-6 and sIL-6R. We present recent examples from animal models in which the therapeutic potential of Hyper-IL-6 has been evaluated. We propose that Hyper-IL-6 can be used to induce potent regeneration responses in liver, kidney, and other tissues and therefore will be a novel therapeutic approach in regenerative medicine.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23456862     DOI: 10.1007/978-1-62703-308-4_4

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  12 in total

1.  Interleukin-6-Mediated Induced Pluripotent Stem Cell (iPSC)-Derived Neural Differentiation.

Authors:  Yanuar Alan Sulistio; Han Kyu Lee; Sung Jun Jung; Klaus Heese
Journal:  Mol Neurobiol       Date:  2017-05-16       Impact factor: 5.590

Review 2.  IL-6 biology: implications for clinical targeting in rheumatic disease.

Authors:  Leonard H Calabrese; Stefan Rose-John
Journal:  Nat Rev Rheumatol       Date:  2014-08-19       Impact factor: 20.543

3.  Preclinical characterization of DUOC-01, a cell therapy product derived from banked umbilical cord blood for use as an adjuvant to umbilical cord blood transplantation for treatment of inherited metabolic diseases.

Authors:  Joanne Kurtzberg; Susan Buntz; Tracy Gentry; Pamela Noeldner; April Ozamiz; Benjamin Rusche; Robert W Storms; Amy Wollish; David A Wenger; Andrew E Balber
Journal:  Cytotherapy       Date:  2015-03-12       Impact factor: 5.414

4.  Hepatocyte Specific gp130 Signalling Underlies APAP Induced Liver Injury.

Authors:  Jinrui Dong; Wei-Wen Lim; Shamini G Shekeran; Jessie Tan; Sze Yun Lim; Joyce Wei Ting Goh; Benjamin L George; Sebastian Schafer; Stuart A Cook; Anissa A Widjaja
Journal:  Int J Mol Sci       Date:  2022-06-25       Impact factor: 6.208

5.  dsRNA Released by Tissue Damage Activates TLR3 to Drive Skin Regeneration.

Authors:  Amanda M Nelson; Sashank K Reddy; Tabetha S Ratliff; M Zulfiquer Hossain; Adiya S Katseff; Amadeus S Zhu; Emily Chang; Sydney R Resnik; Carly Page; Dongwon Kim; Alexander J Whittam; Lloyd S Miller; Luis A Garza
Journal:  Cell Stem Cell       Date:  2015-08-06       Impact factor: 24.633

6.  Interleukin-6 Therapy Improves Intestinal Recovery Following Ischemia.

Authors:  Jan P Te Winkel; Natalie A Drucker; Bryant S Morocho; W Christopher Shelley; Troy A Markel
Journal:  J Surg Res       Date:  2019-03-01       Impact factor: 2.417

7.  Discovery of a junctional epitope antibody that stabilizes IL-6 and gp80 protein:protein interaction and modulates its downstream signaling.

Authors:  Ralph Adams; Rebecca J Burnley; Chiara R Valenzano; Omar Qureshi; Carl Doyle; Simon Lumb; Maria Del Carmen Lopez; Robert Griffin; David McMillan; Richard D Taylor; Chris Meier; Prashant Mori; Laura M Griffin; Ulrich Wernery; Jörg Kinne; Stephen Rapecki; Terry S Baker; Alastair D G Lawson; Michael Wright; Anna Ettorre
Journal:  Sci Rep       Date:  2017-01-30       Impact factor: 4.379

8.  PDGFB-expressing mesenchymal stem cells improve human hematopoietic stem cell engraftment in immunodeficient mice.

Authors:  Xiuxiu Yin; Linping Hu; Yawen Zhang; Caiying Zhu; Hui Cheng; Xiaowei Xie; Ming Shi; Ping Zhu; Xueying Zhao; Wanqiu Chen; Lu Zhang; Cameron Arakaki; Sha Hao; Mei Wang; Wenbin Cao; Shihui Ma; Xiao-Bing Zhang; Tao Cheng
Journal:  Bone Marrow Transplant       Date:  2019-12-05       Impact factor: 5.483

Review 9.  Interleukins in chronic liver disease: lessons learned from experimental mouse models.

Authors:  Linda Hammerich; Frank Tacke
Journal:  Clin Exp Gastroenterol       Date:  2014-09-01

Review 10.  Mesenchymal Stromal Cells and Exosomes: Progress and Challenges.

Authors:  Matthew H Forsberg; John A Kink; Peiman Hematti; Christian M Capitini
Journal:  Front Cell Dev Biol       Date:  2020-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.